News Focus
News Focus
icon url

DewDiligence

01/18/12 3:37 PM

#135294 RE: mouton29 #102024

What hypothesis, if any, for this association between exfoliation glaucoma and latitude?

http://www.ophthalmologyweb.com/1317-Journal-Updates/37147-Demographic-and-Geographic-Features-of-Exfoliation-Glaucoma-in-2-United-States-Based-Prospective-Cohorts/

http://online.wsj.com/article/SB10001424052970204331304577144853241744454.html

Geographical glaucoma: People in the U.S. who spend most of their lives below 41 degrees north latitude, which passes through Chicago, have a significantly lower risk of developing exfoliation glaucoma than residents in more northerly locations, according to research published in the journal Ophthalmology.
Exfoliation glaucoma is characterized by protein deposits in the eye, which clog drainage channels and cause vision loss. Exfoliation glaucoma is the leading cause of a secondary condition and a common form of the disease, open-angle glaucoma.

Boston researchers analyzed data on U.S. residency for 78,955 women and 41,191 men from two national health studies. Participants completed biannual questionnaires from 1980 to 2008. During the study period, 5,022 women and 1,848 men had a physician-confirmed glaucoma diagnosis such as elevated eye pressure, open-angle glaucoma or another type of glaucoma. Exfoliation glaucoma was confirmed in 5.7% of women and 3.3% of men.

Living below 41 degrees north latitude was associated with a 47% reduced risk of suspected or confirmed exfoliation glaucoma, and below 37 degrees north latitude, which passes through San Francisco, with a 75% reduced risk. Men were 68% less likely to develop the condition than women.

Researchers determined that iris color and ancestry weren't risk factors. Identifying environmental factors in glaucoma could reduce vision loss, researchers said.

Caveat: The relationship of eye color and glaucoma was examined only in men. Iris color was self-reported by the subjects so classification errors are possible, the researchers said.

icon url

DewDiligence

04/03/12 1:17 PM

#139685 RE: mouton29 #102024

WPI challenges AGN’s patents on Lumigan and Latisse (which consist of the same active ingredient):

http://finance.yahoo.com/news/watson-confirms-lumigan-r-latisse-131500891.html

This patent challenge is somewhat unusual insofar as AGN already prevailed against Teva in a similar challenge that was decided in Sep 2011 (#msg-66939879). Teva is the best in the business at challenging patents, so WPI presumably has a novel argument to make to the Court.

AGN has two formulations of Lumigan at concentrations of 0.03% (approved in 2001) and 0.01% (approved in 2010); AGN’s goal is to switch patients from the former to the latter, which purportedly has equivalent efficacy with better tolerability. The entire franchise—consisting of Latisse and the two formulations of Lumigan—is generating about $500M in annual US sales, of which about 80% comes from Lumigan. (However, Latisse has considerable upside as a potential treatment for androgenetic alopecia—i.e. male/female pattern baldness.)

Lumigan (but not Latisse) has an Orange-Book CoM patent (5688819) expiring in Aug 2014; both products have a CoM patent (6403649) expiring in Sep 2012 and several “use” patents expiring much later. The AGN-Teva litigation decided in AGN’s favor included both the ‘649 and ‘819 patents.